A randomized, double-blind, placebo-controlled study of cd4 monoclonal antibody therapy in early rheumatoid arthritis

Antibody Therapy ◽

Controlled Study ◽

Monoclonal Antibody Therapy ◽

Double Blind ◽

Infliximab for 6 months added on combination therapy in early rheumatoid arthritis: 2-year results from an investigator-initiated, randomised, double-blind, placebo-controlled study (the NEO-RACo Study)

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2012-201365 ◽

2012 ◽

Vol 72 (6) ◽

pp. 851-857 ◽

Cited By ~ 56

Author(s):

Marjatta Leirisalo-Repo ◽

Hannu Kautiainen ◽

Leena Laasonen ◽

Markku Korpela ◽

Markku J Kauppi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Combination Therapy ◽

Controlled Study ◽

Double Blind ◽

Anti–interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study

Arthritis & Rheumatism ◽

10.1002/art.21826 ◽

2006 ◽

Vol 54 (6) ◽

pp. 1778-1785 ◽

Cited By ~ 28

Author(s):

Rainer H. Straub ◽

Peter Härle ◽

Seizo Yamana ◽

Takemasa Matsuda ◽

Kiyoshi Takasugi ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Interleukin 6 ◽

Antibody Therapy ◽

Controlled Study ◽

Adrenal Androgen ◽

Double Blind ◽

Double Blind Placebo ◽

Receptor Antibody ◽

Interleukin 6 Receptor ◽

Androgen Secretion

MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments

Arthritis Research & Therapy ◽

10.1186/ar3502 ◽

2011 ◽

Vol 13 (5) ◽

Cited By ~ 15

Author(s):

Heleen Scheerens ◽

Zheng Su ◽

Bryan Irving ◽

Michael J Townsend ◽

Yanan Zheng ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase I ◽

Controlled Study ◽

Double Blind ◽

A phase II, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of MDX-1100, a fully human anti-CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis

Arthritis & Rheumatism ◽

10.1002/art.34330 ◽

2012 ◽

Vol 64 (6) ◽

pp. 1730-1739 ◽

Cited By ~ 100

Author(s):

Michael Yellin ◽

Igor Paliienko ◽

Andra Balanescu ◽

Semen Ter-Vartanian ◽

Vira Tseluyko ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Phase Ii ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Results of A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of The Efficacy And Safety of Sirukumab, An Anti-IL-6 Cytokine Monoclonal Antibody, In Patients with Active Rheumatoid Arthritis Despite Disease-Modifying Anti-Rheumatic Drug Treatment (Sirround-D)

Value in Health ◽

10.1016/j.jval.2016.09.1074 ◽

2016 ◽

Vol 19 (7) ◽

pp. A531 ◽

Cited By ~ 2

Author(s):

T Takeuchi ◽

C Thorne ◽

G Karpouzas ◽

S Sheng ◽

W Xu ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Monoclonal Antibody ◽

Active Rheumatoid Arthritis ◽

Controlled Study ◽

Efficacy And Safety ◽

Phase 3 ◽

Double Blind ◽

Double Blind Placebo ◽

Disease Modifying ◽

Rheumatic Drug

Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study

Annals of the Rheumatic Diseases ◽

10.1136/ard.2008.106484 ◽

2009 ◽

Vol 68 (12) ◽

pp. 1898-1901 ◽

Cited By ~ 52

Author(s):

G Haugeberg ◽

P G Conaghan ◽

M Quinn ◽

P Emery

Keyword(s):

Rheumatoid Arthritis ◽

Bone Loss ◽

Controlled Study ◽

Double Blind ◽

Double Blind Placebo ◽

Methotrexate Treatment

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis

The Pharmacogenomics Journal ◽

10.1038/tpj.2015.30 ◽

2015 ◽

Vol 16 (2) ◽

pp. 141-146 ◽

Cited By ~ 34

Author(s):

S B Krintel ◽

C Dehlendorff ◽

M L Hetland ◽

K Hørslev-Petersen ◽

K K Andersen ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Treatment Response ◽

Controlled Study ◽

Circulating Microrna ◽

Double Blind ◽

Vitamin D and immunomodulation in early rheumatoid arthritis: A randomized double-blind placebo-controlled study

PLoS ONE ◽

10.1371/journal.pone.0178463 ◽

2017 ◽

Vol 12 (6) ◽

pp. e0178463 ◽

Cited By ~ 19

Author(s):

Ilaria Buondonno ◽

Guido Rovera ◽

Francesca Sassi ◽

Micol Maria Rigoni ◽

Claudia Lomater ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Vitamin D ◽

Controlled Study ◽

Double Blind ◽

Faculty Opinions recommendation of Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725732407.793547378 ◽

2018 ◽

Author(s):

Maria Laura Bertolaccini

Keyword(s):

Systemic Lupus Erythematosus ◽

Monoclonal Antibody ◽

Lupus Erythematosus ◽

Phase Iii ◽

Controlled Study ◽

Efficacy And Safety ◽

Systemic Lupus ◽

Double Blind ◽

Double Blind Placebo ◽

B Cell Activating Factor

Safety and Efficacy of Monoclonal Antibody VIS410 in Adults with Uncomplicated Influenza A Infection: Results from a Randomised, Double-Blind, Placebo-Controlled Study

SSRN Electronic Journal ◽

10.2139/ssrn.3271424 ◽

2018 ◽

Author(s):

Ellie Hershberger ◽

Susan Sloan ◽

Kristin Narayan ◽

Catherine A. Hay ◽

Patrick Smith ◽

...

Keyword(s):

Monoclonal Antibody ◽

Influenza A ◽

Controlled Study ◽

Double Blind ◽

Safety And Efficacy ◽